Alexis Peyroles MBA CEO Of OSE Immunotherapeutics Discusses TEDOPI: A Patented Combination Of 10 Neo-Epitopes. TEDOPI Is Being Evaluated In NSCLC After Checkpoint Inhibitor Failure.
Advertisement
TEDOPI: A Patented Combination Of 10 Neo-Epitopes. TEDOPI Is Being Evaluated In NSCLC After Checkpoint Inhibitor Failure
By Editor